NEW YORK, Jan. 12, 2011 /PRNewswire/ — InstaCare Corp. (OTC
Bulletin Board: ISCR) a leading provider of prescription and
non-prescription diagnostics, home testing products for the
chronically ill, a leading fulfillment provider of direct to
patient diabetes programs, and a leading developer of revolutionary
cell phone centric e-health products and technologies, today
announced that the company’s Board of Directors has received the
initial Guidance Report from Mr. William N. Walling,
Jr., CFA. This report covers the 2011 guidance for the
company’s new Genstrip diagnostic product being sold exclusively
through the company’s Pharma Tech Solutions, Inc. subsidiary.
The entire report is currently available for viewing on the
company’s website www.instacare.net.
Mr. Walling, an expert financial analyst specializing in the
domestic healthcare paradigm, was contracted to review the
company’s performance, its progress with project development,
product pipeline advancement, new product introduction (Genstrip)
and financial results versus the stated plan. Mr. Walling’s report
includes an expectation of continued strength and market
growth of current product offerings, and substantial industry
traction with the company’s new Genstrip diagnostic product with
substantial revenue and margin contribution potential.
Keith Berman, Secretary and CFO of InstaCare Corp., commented:
“Mr. Walling’s report reinforces our internal confidence in
the company’s business model and strategic direction. This
report concerning our new Genstrip diagnostic product should assure
the investment community and company’s shareholders that management
and the BOD have faithfully executed the tasks documented in our
plan enabling the attainment of all identified benchmarks. It
should also confirm the validity of the company’s business model
and the viability of our continued success going forwa
‘/>”/>
